US2014274961A1PendingUtilityA1
Compounds and uses thereof for the modulation of hemoglobin
Assignee: GLOBAL BLOOD THERAPEUTICS INCPriority: Mar 15, 2013Filed: Mar 15, 2013Published: Sep 18, 2014
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
C07F 9/65583C07D 401/04
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Claims
exact text as granted — not AI-modified1 . A compound of formula (I):
or an N oxide thereof, or a pharmaceutically acceptable salt of each thereof, wherein
A is selected from the group consisting of:
wherein R 1 is C 1 -C 6 alkyl optionally substituted with 3-6 fluoro atoms;
R 2 is hydrogen or C 1 -C 6 alkyl;
R 3 is C 1 -C 6 alkyl;
each R 4 independently is hydrogen or C 1 -C 6 alkyl;
ring B is
or ring B together with A is:
X is oxygen, S, SO, or SO 2 ;
ring C is selected from the group consisting of:
wherein R 5 is selected from the group consisting of hydrogen; C 1 -C 6 alkoxy, optionally substituted with a C 1 -C 6 alkoxy group or with up to 3 fluoro atoms; C 1 -C 6 alkyl; and halo;
R 6 is hydrogen or halo;
R is hydrogen, a phosphate, a diphosphate, a phosphonate or a phosphoramidate containing moiety, or another promoiety;
provided that the compound of formula (I) comprises at least 1 OR group where R is not hydrogen.
2 . The compound of claim 1 , of formula (II):
wherein R and R 1 are defined as in claim 1 .
3 . The compound of claim 1 , wherein R is —C(O)R 31 , C(O)OR 31 , or CONR 13 R 14 wherein each R 31 is independently a C 1 -C 6 alkyl; C 3 -C 8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, containing at least 1 basic nitrogen moiety; and
R 13 and R 14 independently are C 1 -C 6 alkyl; C 3 -C 8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, containing at least 1 basic nitrogen moiety; or R 13 and R 14 together with the nitrogen atom they are bonded to for a 4-9 member heterocycle substituted with at least 1 amino, C 1 -C 6 alkyl amino, or di C 1 -C 6 alkylamino group.
4 . The compound of claim 1 , wherein R 1 is isopropyl.
5 . A compound of formula (II):
wherein R is phosphate, C(O)(CH 2 ) m NR 34 R 35 , or C(O)O(CH 2 ) m NR 34 R 35 ; and
wherein m, R 1 , R 34 and R 35 are defined as tabulated below:
R
R 1
m
R 34
R 35
NR 34 R 35
C(O)(CH 2 ) m NR 34 R 35
iso-
2
Me
Me
propyl
C(O)(CH 2 ) m NR 34 R 35
iso-
3
Me
Me
propyl
C(O)(CH 2 ) m NR 34 R 35
iso-
4
Me
Me
propyl
C(O)(CH 2 ) m NR 34 R 35
iso- propyl
2
C(O)(CH 2 ) m NR 34 R 35
iso- propyl
3
C(O)(CH 2 ) m NR 34 R 35
iso- propyl
4
C(O)O(CH 2 ) m NR 34 R 35
iso-
2
Me
Me
propyl
C(O)O(CH 2 ) m NR 34 R 35
iso-
3
Me
Me
propyl
C(O)O(CH 2 ) m NR 34 R 35
iso-
4
Me
Me
propyl
C(O)O(CH 2 ) m NR 34 R 35
iso- propyl
2
C(O)O(CH 2 ) m NR 34 R 35
iso- propyl
3
C(O)O(CH 2 ) m NR 34 R 35
iso- propyl
4
P(O)(OH) 2
iso- propyl
an N oxide thereof, or a pharmaceutically acceptable salt of each thereof.
6 . A composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.
7 . A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .
8 . A method for treating oxygen deficiency associated with sickle cell anemia, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .Join the waitlist — get patent alerts
Track US2014274961A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.